Literature DB >> 17259472

The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes.

Peter C Tong1, Alice P Kong, Wing-Yee So, Xilin Yang, Chung-Shun Ho, Ronald C Ma, Risa Ozaki, Chun-Chung Chow, Christopher W Lam, Juliana C N Chan, Clive S Cockram.   

Abstract

OBJECTIVE: The purpose of this study was to compare the predictive value for coronary heart disease (CHD) of the International Diabetes Federation (IDF) definition (with Asian criteria for central obesity) of the metabolic syndrome with existing criteria of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) in Chinese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: Subjects with type 2 diabetes and without macrovascular diseases or end-stage renal disease were categorized by the criteria of the IDF and the NCEP ATP III. CHD was defined as myocardial infarction, ischemic heart disease, coronary revascularization, heart failure, and death related to CHD.
RESULTS: Of 4,350 patients (aged 54.4 +/- 13.4 years; median follow-up period 7.1 [interquartile range 5.2-8.5] years), 65.9% had metabolic syndrome according to either IDF or NCEP ATP III criteria. The NCEP ATP III definition identified metabolic syndrome in 786 subjects (18.1%) who did not fulfill the criteria of the IDF. HDL cholesterol and systolic blood pressure were predictors of CHD after adjustment for other confounding factors. Compared with subjects without metabolic syndrome, the IDF criteria failed to predict CHD (hazard ratio 1.13 [95% CI 0.86-1.48], P = 0.374). In contrast, the NCEP ATP III definition (2.51 [1.80-3.50], P < 0.001) predicted an increased risk of CHD with the NCEP-only group having the highest risk (2.49 [1.66-3.73], P < 0.001).
CONCLUSIONS: With established type 2 diabetes, the IDF definition of the metabolic syndrome failed to identify a subgroup of patients who had the highest risk for CHD. Practitioners must recognize the appropriate setting for its application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17259472     DOI: 10.2337/dc06-1484

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  31 in total

1.  Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome.

Authors:  Nadia Rashid; Aruna Nigam; Pikee Saxena; S K Jain; Saima Wajid
Journal:  Inflamm Res       Date:  2017-04-12       Impact factor: 4.575

Review 2.  Cardiovascular risk in the metabolic syndrome: fact or fiction?

Authors:  Peter M Nilsson
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

3.  Taste sensitivity, nutritional status and metabolic syndrome: Implication in weight loss dietary interventions.

Authors:  Simona Bertoli; Monica Laureati; Alberto Battezzati; Valentina Bergamaschi; Emanuele Cereda; Angela Spadafranca; Laila Vignati; Ella Pagliarini
Journal:  World J Diabetes       Date:  2014-10-15

4.  Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner.

Authors:  Eduardo Guimarães Hourneaux de Moura; Ivan Roberto Bonotto Orso; Bruno da Costa Martins; Guilherme Sauniti Lopes; Suzana Lopes de Oliveira; Manoel dos Passos Galvão-Neto; Marcio Correa Mancini; Marco Aurélio Santo; Paulo Sakai; Almino Cardoso Ramos; Arthur Belarmino Garrido-Júnior; Alfredo Halpern; Ivan Cecconello
Journal:  Obes Surg       Date:  2011-07       Impact factor: 4.129

5.  Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Todd M Brown; Jenifer H Voeks; Vera Bittner; Monika M Safford
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

6.  Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.

Authors:  Jiun-Hung Geng; Anna Plym; Kathryn L Penney; Mark Pomerantz; Lorelei A Mucci; Adam S Kibel
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-24       Impact factor: 5.554

7.  The effectiveness of IDF and ATP-III in identifying metabolic syndrome and the usefulness of these tools for health-promotion in older Taiwanese.

Authors:  M M Chen; A C Tsai
Journal:  J Nutr Health Aging       Date:  2013-04       Impact factor: 4.075

8.  A novel nonparametric approach for estimating cut-offs in continuous risk indicators with application to diabetes epidemiology.

Authors:  Jens Klotsche; Dietmar Ferger; Lars Pieper; Jürgen Rehm; Hans-Ulrich Wittchen
Journal:  BMC Med Res Methodol       Date:  2009-09-10       Impact factor: 4.615

9.  Differential impact of metabolic syndrome on subclinical atherosclerosis according to the presence of diabetes.

Authors:  Ki-Bum Won; Hyuk-Jae Chang; Hyeon-Chang Kim; Kyewon Jeon; Hancheol Lee; Sanghoon Shin; In-Jeong Cho; Sung-Ha Park; Sang-Hak Lee; Yangsoo Jang
Journal:  Cardiovasc Diabetol       Date:  2013-03-04       Impact factor: 9.951

10.  Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index.

Authors:  Pikee Saxena; Anupam Prakash; Aruna Nigam; Archana Mishra
Journal:  Indian J Endocrinol Metab       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.